Top news of the day from across the health care landscape.
Continuous infusion dosing of ceftolozane/tazobactam (C/T) is a safe, well-tolerated, and convenient way to treat infections caused by multidrug-resistant Pseudomonas aeruginosa, according to Contagion Live. A retrospective chart review included 7 patients evaluated between August 2016 who received either 4.5 g or 9 g of continuous infusion C/T every 24 hours in the outpatient setting. The study showed that 6 out of 7 patients had symptom resolution, and 3 out of 3 had microbiologic resolution.
A review suggests that more than 2 million US adults with cardiovascular disease had reported using marijuana, in spite of previous data indicating its potential negative impact on cardiovascular health, according to MD Magazine. The study authors found the correlation after conducting a review of 89.6 million adults through the National Health and Nutrition Examination Survey between 2005 and 2016. An additional systematic review of 33 studies indicated 28 found an association between increased risk of acute coronary syndromes and marijuana use.
An RNA gene, miR-543, plays a significant role in the epigenetic landscape of myelofibrosis (MF), specifically via its targeting of 10-11 translation 1 and 2, according to The American Journal of Managed Care. Researchers performed transcription-quantitative polymerase chain reaction in 107 patients with MF treated with ruxolitinb. The findings suggest miR-543 as a potentially novel biomarker for the prognosis of patients with MF who have a high risk of treatment resistance and as a potentially new target for the development of new treatment options.